NYSE : BSX
Boston Scientific Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 41.98 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 60.84B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 63.80B |
| Enterprise Value | 75.89B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.45B |
| Shares Outstanding | 1.45B |
| Shares Change (YoY) | -0.91% |
| Shares Change (QoQ) | -1.55% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 93.36% |
| Float | 1.44B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 18.59 |
| Forward PE | 14.28 |
| PS Ratio | 2.89 |
| Forward PS | 2.95 |
| PB Ratio | 2.44 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.78 |
| P/OCF Ratio | 13.43 |
| PEG Ratio | 1.32 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 20.82 |
| EV / Sales | 3.46 |
| EV / EBITDA | 12.81 |
| EV / EBIT | 17.10 |
| EV / FCF | 20.12 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.24 |
| Quick Ratio | 0.56 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 2.22 |
| Debt / FCF | 3.48 |
| Interest Coverage | 11.37 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 15.34% |
| Return on Assets (ROA) | 6.19% |
| Return on Invested Capital (ROIC) | 10.94% |
| Return on Capital Employed (ROCE) | 11.08% |
| Weighted Average Cost of Capital (WACC) | 6.63% |
| Revenue Per Employee | $357,119 |
| Profits Per Employee | $59,356 |
| Employee Count | 59,000 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.12 |
Taxes
| Measure | Value |
|---|
| Income Tax | 162.00M |
| Effective Tax Rate | 4.43% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | -56.22% |
| 50-Day Moving Average | 44.67 |
| 200-Day Moving Average | 56.29 |
| Relative Strength Index (RSI) | 49.95 |
| Average Volume (20 Days) | 17,838,219 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 40.71M |
| Short Previous Month | 46.50M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.82% |
| Short Ratio (days to cover) | 2.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 21.07B |
| Gross Profit | 14.45B |
| Operating Income | 4.26B |
| Pretax Income | 3.66B |
| Net Income | 3.50B |
| EBITDA | 5.69B |
| EBIT | 4.26B |
| Earnings Per Share (EPS) | $2.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 539.00M |
| Total Debt | 12.62B |
| Net Cash | -12.09B |
| Net Cash Per Share | -$8.34 |
| Equity (Book Value) | 25.17B |
| Book Value Per Share | 17.23 |
| Working Capital | 1.54B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 4.53B |
| Capital Expenditures | -904.00M |
| Depreciation & Amortization | 1.43B |
| Net Borrowing | 978.00M |
| Free Cash Flow | 3.63B |
| FCF Per Share | $2.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.58% |
| Operating Margin | 20.24% |
| Pretax Margin | 17.35% |
| Profit Margin | 16.62% |
| EBITDA Margin | 27.02% |
| EBIT Margin | 20.24% |
| FCF Margin | 17.27% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.91% |
| Shareholder Yield | 0.91% |
| Earnings Yield | 5.38% |
| FCF Yield | 5.96% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.60 |
| Price Target Difference | 12.66% |
| Analyst Consensus | Buy |
| Analyst Count | 31 |
| Revenue Growth Forecast (3Y) | 3.16% |
| EPS Growth Forecast (3Y) | 3.30% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 6, 2003 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |